SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials - Zelniker, T A; Wiviott, S D; Raz, I (Lancet, 2019)
et al.